Florida is currently home to 3831 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Registry for People With T-cell Lymphoma
NCT05978141
Recruiting
The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.
Gender:
ALL
Ages:
All
Trial Updated:
05/16/2025
Locations: University of Miami (Data Collection Only), Miami, Florida
Conditions: T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocytic Leukemia, Chronic Lymphoproliferative Disorder of NK Cells, Aggressive NK-cell Leukemia, Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder), Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood, Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Adult T-cell Leukemia/Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Enteropathy-associated T-cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Intestinal T-Cell Lymphoma, Not Otherwise Specified, Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma, Primary Cutaneous T-cell Lymphoma, Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma, Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Breast Implant-Associated Anaplastic Large Cell Lymphoma
Register for Updates
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
NCT05541822
Recruiting
ABN401-003 is a Phase 2 clinical study to assess efficacy, safety, tolerability and pharmacokinetic profile of ABN401 (vabametkib) in specific populations of advance solid tumors with c-MET alterations as monotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Cancer Care of North Florida, PA (Lake City Cancer Care, LLC) - Medical Oncology, Lake City, Florida
Conditions: Advanced Solid Tumors
Register for Updates
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
NCT05296070
Recruiting
The purpose of this research study is to see if loncastuximab tesirine has any benefits at dose levels researchers found acceptable in earlier studies in patients with related forms of immune cell cancers. The researchers want to find out the effects (good and bad) that loncastuximab tesirine has on the participant and the participant's condition.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: University of Miami, Miami, Florida
Conditions: Marginal Zone Lymphoma
Register for Updates
Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia
NCT05179226
Recruiting
Several clinical trials have been reported for ferric derisomaltose where it has been shown to be well tolerated and to improve markers of IDA. All clinical trials with ferric derisomaltose have been performed in adults, however, IDA is not specific to the adult population. In fact, children are likely to develop IDA due to their rapid growth. The aim in this trial is to evaluate the efficacy and safety of intravenous (IV) ferric derisomaltose in children 0 to \<18 years of age with IDA due to... Read More
Gender:
ALL
Ages:
17 years and below
Trial Updated:
05/16/2025
Locations: Pharmacosmos Investigational Site, Miami, Florida
Conditions: Iron Deficiency, Anaemia in Children
Register for Updates
Parkinson's Foundation PD GENEration Genetic Registry
NCT04994015
Recruiting
Development of a central repository for PD-related genomic data for future research.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Aventura Neurology - Visionary Investigators Network, Aventura, Florida
Conditions: Parkinson's Disease
Register for Updates
Mechanisms and Modulation of Pain Modulatory Capacity
NCT04441619
Recruiting
This project proposes to understand the sources of pain variability, and demonstrate that pain variability represents fluctuation in natural pain management. The project further proposes to determine if endogenous capacity to modulate pain can be trained to maximize their body's ability to manage pain, much as the way in which athletic performance can be trained.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/16/2025
Locations: Unversity of Florida, Gainesville, Florida
Conditions: Musculoskeletal Pain
Register for Updates
Systemic Hypothermia in Acute Cervical Spinal Cord Injury
NCT02991690
Recruiting
This study is a prospective multi-center trial designed to determine the safety profile and efficacy of modest (33ºC) intravascular hypothermia following acute cervical (C1 to C8) Spinal Cord Injury (SCI).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/16/2025
Locations: Jackson Memorial Hospital, Miami, Florida
Conditions: Spinal Cord Injury, Acute
Register for Updates
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
NCT06952699
Recruiting
Narcolepsy without cataplexy or Narcolepsy Type 2 (NT2) is a lifelong condition that makes people very sleepy during the day, regardless of how much sleep they get at night. People with NT2 may fall asleep suddenly, have trouble staying awake during the day, or may not be able to sleep well at night. They may have difficulty thinking clearly, paying attention, or remembering things, during the day. These symptoms can make daily activities like driving, working, or caring for their families chall... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/15/2025
Locations: Takeda Site 13, Brandon, Florida
Conditions: Narcolepsy Type 2
Register for Updates
Sweet Corn and Carotenoids
NCT06892444
Recruiting
This study will assess the effect of daily yellow and white sweet corn intake on serum lutein and zeaxanthin concentrations. Skin carotenoid levels using the Veggie Meter will be assessed, and gastrointestinal symptoms and changes in fecal microbiota during a 4-week intervention period will be monitored.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
05/15/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Carotenoids
Register for Updates
Pulsed Electromagnetic Field Treatment With Dementia Patients
NCT06862557
Recruiting
An open label pilot study in mild to moderate AD/ADRD patients to assess the effects of treatment with ECHS AD/ADRD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices. They will treat themselves at home three times a day for 15 minutes over 120 days. Primary end point is the The Alzheimer's Disease Assessment Scale-Cognitive Subscale. Participants will be followed-up for 9 months post-treatment.
Gender:
ALL
Ages:
Between 50 years and 100 years
Trial Updated:
05/15/2025
Locations: University of Miami, Boca Raton, Florida
Conditions: Alzheimer's Disease, Lewy Body Dementia, Vascular Dementia
Register for Updates
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314
Recruiting
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the format... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Holy Cross Hospital, Fort Lauderdale, Florida
Conditions: Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian High Grade Endometrioid Adenocarcinoma
Register for Updates
DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients
NCT06388122
Recruiting
The purpose of this study is to explore the clinical utility of routinely measuring thymidine kinase activity (TKa) in HR+ metastatic breast cancer patients receiving treatment with any approved endocrine therapy either alone or in combination with any approved CDK4/6 inhibitor.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: HER2-negative Breast Cancer, Hormone-receptor-positive Breast Cancer, Metastatic Breast Cancer
Register for Updates